2025
Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study
Dribin T, Sampson H, Zhang Y, Boyd S, Zhang N, Michelson K, Neuman M, Brousseau D, Mistry R, Freedman S, Aronson P, Bergmann K, Boswell B, Chinta S, Chua W, Cohen A, Cohen J, Daggett A, Davis J, Freeman J, Khanna K, Knoles C, Kwan K, Larsen C, Lee J, Lubell T, Metcalf A, Moake M, Nesiama J, Ngo T, Pulcini C, Russo C, Singh N, Srivastava G, Strutt J, Thapar V, Vander Wyst C, Walsh P, Wolnerman Y, Schnadower D, Academy of Pediatrics P, Kanngiesser A, McGarghan F, Dulchavsky A, Costalez J, DesPain A, Armanious M, Haghnazarian E, Brown-Whitehorn T, Weigert R, Dayan P, Meltzer J, Chowdhury N, Benedetti J, Sinziana C, Handorf A, Ruthford M, Devens M, Mecham C, Holland J, Casas T, Brown J, Panda P, Morrow A, Maready M, Nathani Y, Stevens M, Abraham G, Yen K, Cooper-Sood J, Woolf S. Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. The Lancet Child & Adolescent Health 2025, 9: 484-496. PMID: 40506197, DOI: 10.1016/s2352-4642(25)00139-7.Peer-Reviewed Original ResearchConceptsElectronic medical recordsEmergency departmentRetrospective cohort studyCohort studyMedical recordsDocumentation of symptomsCardiovascular involvementHealth-care facilitiesEpinephrine doseAcute allergic reactionsNational Institutes of HealthCumulative incidenceNational Center for Advancing Translational SciencesInstitutes of HealthChildren Aged 6 MonthsClinical ModificationHospital wardsIncidence rateICD-10Observation periodPrimary outcomeAllergic reactionsSecondary to medicationsInitiation to discontinuationKaplan-Meier analysisRisk of unprovoked seizures after discontinuation of antiseizure medication at discharge following acute symptomatic seizures
Punia V, Byrnes M, Thompson N, Ayub N, Rubinos C, Zafar S, Sivaraju A, investigators F. Risk of unprovoked seizures after discontinuation of antiseizure medication at discharge following acute symptomatic seizures. Epilepsia 2025 PMID: 40387211, DOI: 10.1111/epi.18464.Peer-Reviewed Original ResearchAcute symptomatic seizuresAntiseizure medicationsUnprovoked seizuresRisk of unprovoked seizuresSymptomatic seizuresAssociated with electrographic seizuresMedian Follow-UpRetrospective cohort studyCox proportional hazards modelsCause-specific Cox proportional hazards modelsProportional hazards modelIncidence of unprovoked seizuresASyS patientsConsecutive adultsSingle-centerElectrographic seizuresNo significant differenceCumulative incidenceFollow-upCohort studyPatient populationFunctional outcomesSeizure riskPatientsHospital dischargeDiabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia
Callegari S, Romain G, Aggarwal A, Cleman J, Smolderen K, Mena-Hurtado C. Diabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia. Journal Of Vascular Surgery 2025 PMID: 40348290, DOI: 10.1016/j.jvs.2025.04.065.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaLower-extremity bypassSub-hazard ratiosPeripheral vascular interventionsDM statusRisk of deathLimb-threatening ischemiaTeam-based careShared decision-makingCumulative incidenceDiabetes mellitusMedicare claims dataCumulative incidence of mortalityAll-Cause MortalityType of revascularizationAmputation outcomesCare offerFine-Gray modelClaims dataCumulative incidence of deathLong-term mortalityMortality riskCox regression modelsHazard ratioDiabetes statusA Comparative Assessment of Molecular-Based Prognostic Models in CMML
Aguirre L, Al Ali N, Ball S, Jain A, Sallman D, Kuykendall A, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. A Comparative Assessment of Molecular-Based Prognostic Models in CMML. Blood Neoplasia 2025, 100116. DOI: 10.1016/j.bneo.2025.100116.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaIPSS-MMedian overall survivalCPSS-MolMyelodysplastic syndromePrognostic accuracyCumulative incidenceChronic myelomonocytic leukemia patientsHypomethylating agent therapyIPSS-RAML evolutionAgent therapyLeukemic evolutionOverall survivalMyelomonocytic leukemiaRisk stratificationFrequent mutationsTreatment decisionsPrognostic modelPrognostic systemPatientsRisk categoriesMolecular dataRiskTreatmentAssociation of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker Research 2025, 13: 64. PMID: 40275414, PMCID: PMC12023351, DOI: 10.1186/s40364-025-00780-4.Peer-Reviewed Original ResearchLymphoma-specific survivalOverall survivalCAR-TRelative survivalChimeric antigen receptor T cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaCumulative incidence of deathB-cell lymphomaPopulation-based cohort studyReceipt of chemotherapyIncidence of deathPeriod of diagnosisRefractory DLBCLB symptomsMultivariate survival modelsMedian ageT cellsImproved survivalCumulative incidenceSEER-17Disease courseCohort studyDisease stageFDA approvalTarget Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-Cause MortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination statusDifferences in patterns of outpatient epilepsy‐specific medication initiation after acute ischemic stroke in the Medicare population
Donahue M, Brooks J, Hsu J, Price M, Blacker D, Schwamm L, Newhouse J, Westover M, Haneuse S, Moura L. Differences in patterns of outpatient epilepsy‐specific medication initiation after acute ischemic stroke in the Medicare population. Epilepsia 2025 PMID: 40184019, DOI: 10.1111/epi.18396.Peer-Reviewed Original ResearchNon-Hispanic whitesOlder age groupsAcute ischemic strokeAge groupsCommunity-dwelling beneficiariesNon-Hispanic white beneficiariesUS Medicare beneficiariesCumulative incidenceYear of dischargeUS geographic regionsAdministrative claims dataUS census divisionsIschemic strokeHospitalization causeRacial/Ethnic DifferencesMedicare beneficiariesOlder adultsWhite beneficiariesBlack/African AmericanMedicare populationClaims dataHispanic beneficiariesHospital regionMedication initiationInpatient readmissionsDevelopment of the natural history component of an early economic model for primary sclerosing cholangitis
Bowlus C, Levy C, Kowdley K, Kachru N, Jeyakumar S, Rodriguez-Guadarrama Y, Smith N, Briggs A, Sculpher M, Ollendorf D. Development of the natural history component of an early economic model for primary sclerosing cholangitis. Orphanet Journal Of Rare Diseases 2025, 20: 133. PMID: 40102907, PMCID: PMC11921552, DOI: 10.1186/s13023-025-03658-8.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTransplant-free survivalProportion of patientsRecurrent PSCLiver transplantationDisease progressionOverall survivalSclerosing cholangitisSecondary cancersCumulative incidenceCumulative incidence of secondary cancersIncidence of secondary cancersChronic cholestatic diseasePrimary sclerosing cholangitisProgression to cirrhosisLifetime quality-adjusted life yearsBackgroundPrimary sclerosing cholangitisMarkov cohort modelInflammatory bowel diseaseEconomic modelGallbladder cancerEstimates of disease progressionCholestatic diseasesFibrosis stageLiver failureSeverity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine 2025, 185: 324-334. PMID: 39869355, PMCID: PMC11773409, DOI: 10.1001/jamainternmed.2024.7452.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusLong-term mortalitySARS-CoV-2Syncytial virusCohort studyAssociated with higher long-term mortalityRisk differenceIntensive care unit admissionSeasonal influenza vaccineRetrospective cohort studyDisease severity of COVID-19Long-term deathAssociated with more severe disease outcomesRisk of deathCompare disease severitySevere disease outcomesRisk of hospitalizationSeverity of COVID-19Same-day testingInfluenza vaccineInverse probability weightingUnit admissionCumulative incidenceMortality of COVID-19Primary outcomeUsing Radiology as a Screening Tool to Identify Intimate Partner Violence
Lenehan P, Tang A, Watane G, Gujrathi R, Park H, Gosangi B, Thomas R, Franco F, Patel K, Warsofsky I, Rosner B, Khurana B. Using Radiology as a Screening Tool to Identify Intimate Partner Violence. Journal Of The American College Of Radiology 2025, 22: 395-404. PMID: 40044319, PMCID: PMC11887577, DOI: 10.1016/j.jacr.2025.01.003.Peer-Reviewed Original ResearchConceptsAdjusted incidence rate ratiosEmergency departmentRetrospective case-control studyImaging utilization patternsEvident injuriesCox proportional hazards regressionRace-matched controlsCase-control studyTime-to-event analysisProportional hazards regressionImaging utilizationIncidence rate ratiosCumulative incidenceAnatomical sitesScreening mammogramsHazards regressionOdds ratioImaging studiesIntimate partner violencePatientsInjury patternsLogistic regressionInjuryOrgan systemsPoisson regressionClinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
Serper M, Tang H, Zhang S, McCullough A, Kaplan D, Taddei T, Mahmud N. Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study. Hepatology 2025 PMID: 39879583, DOI: 10.1097/hep.0000000000001251.Peer-Reviewed Original ResearchIn-Hospital MortalityImprove care outcomesPopulation-based studyNational cohort studyQuality measuresHazard of mortalityPost-discharge mortalityNational cohort of patientsCare outcomesSpontaneous bacterial peritonitisInformal careHealth systemPatient clinical factorsAcute kidney injuryBundle componentsRecurrent spontaneous bacterial peritonitisNational cohortCohort studyIncidence of stage 3In-HospitalClinical factorsStage 3Cohort of patientsCumulative incidenceBacterial peritonitis
2024
Chiropractic Spinal Manipulation and Fall Risk in Older Adults With Spinal Pain: Observational Findings From a Matched Retrospective Cohort Study
Trager R, Burton W, Loewenthal J, Perez J, Lisi A, Kowalski M, Wayne P. Chiropractic Spinal Manipulation and Fall Risk in Older Adults With Spinal Pain: Observational Findings From a Matched Retrospective Cohort Study. Cureus 2024, 16: e72330. PMID: 39583476, PMCID: PMC11585376, DOI: 10.7759/cureus.72330.Peer-Reviewed Original ResearchSpinal manipulative therapyNegative control outcomesSpinal painFall riskRisk ratioOlder adultsLimb fracturesChiropractic spinal manipulative therapyCumulative incidence of fallsChiropractic spinal manipulationFall risk factorsReducing fall riskIncidence of fallsAssociated with fallsControl outcomesRandomized Controlled TrialsSpinal manipulationManipulative therapyInjurious fallsCumulative incidenceCare utilizationRetrospective cohort studyFracture incidenceCohort studyControlled TrialsLenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e131-e142. PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemDose of lenalidomideMyelodysplastic syndromeIsolated del(5qAcute myeloid leukemiaBenefit-risk profileSafety populationTransfusion-DependentOverall survivalCumulative incidenceCumulative incidence of acute myeloid leukemiaGrade 3/4 treatment-emergent adverse eventsNon-interventional post-authorization safety studyInternational Prognostic Scoring System low-Intermediate-1-risk myelodysplastic syndromeIncidence of acute myeloid leukemiaLower-risk myelodysplastic syndromesTreatment-emergent adverse eventsEffects of lenalidomidePrognostic scoring systemKaplan-Meier analysisPost-authorization safety studyRoutine careClinical trial dataSafety surveillance studyRisk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.Peer-Reviewed Original ResearchConceptsRisk of bleedingClinically relevant nonmajor bleedingEssential thrombocythemiaBleeding riskPlatelet countCumulative incidenceDana-Farber Cancer Institute and Massachusetts General HospitalAssociated with acquired von Willebrand syndromeCumulative incidence of thrombosisCumulative incidence of bleedingIncreased bleeding riskIncidence of bleedingReduced bleeding riskVon Willebrand syndromeIncidence of thrombosisNonmajor bleedingDNMT3A mutationsMassachusetts General HospitalThrombotic eventsDana-FarberDiabetes mellitusBleedingPatientsRisk factorsTreatment decisionsInterventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration
Toenges R, Lang F, Ghaffar R, Lindner S, Schlipfenbacher V, Riemann J, Ajib S, Kouidri K, Cremer A, Weber B, Nguyen N, Knoch A, Vehreschild J, Serve H, Bug G. Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration. Annals Of Hematology 2024, 103: 4687-4699. PMID: 39237814, DOI: 10.1007/s00277-024-05986-4.Peer-Reviewed Original ResearchGraft-versus-host diseaseSystemic antibiotic prophylaxisNon-relapse mortalityChronic graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationStem cell transplantationClostridium difficile infectionAntibiotic prophylaxisOverall survivalCumulative incidenceBloodstream infectionsCell transplantationAntibiotic treatmentCumulative incidence of acute GVHD grades II-IVSevere chronic graft-versus-host diseaseRisk of graft-versus-host diseaseAcute GVHD grade II-IVGVHD grade II-IVDuration of antibiotic therapyRisk of infection-related mortalityPre-engraftment periodGrade II-IVMedian Follow-UpInfection-related mortalityMechanical versus biological mitral valve replacement: Insights from propensity score matching on survival and reoperation rates
Feirer N, Buchner A, Weber M, Lang M, Dzilic E, Amabile A, Geirsson A, Trenkwalder T, Krane M, Vitanova K. Mechanical versus biological mitral valve replacement: Insights from propensity score matching on survival and reoperation rates. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 1717-1727. PMID: 39067811, DOI: 10.1016/j.jtcvs.2024.07.038.Peer-Reviewed Original ResearchMitral valve replacementBiological mitral valve replacementPropensity-score matchingValve replacementReoperation rateCumulative incidenceFollow-upMechanical mitral valve replacementMedian follow-up timeCumulative incidence of reoperationSurgical mitral valve replacementSymptomatic mitral valve diseaseIncidence of reoperationThirty-day mortalityHigh-volume centersMitral valve diseaseHistory of neurological disordersPropensity score matchingAnalyzed time pointsConcomitant proceduresPeriprocedural complicationsSingle-centerThirty-dayRetrospective studyReoperationRisk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatientsOutcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T. A, Allegretti A, Cullaro G, Ouyang T, Asrani S, Chung R, Przybyszewski E, Wilechansky R, Robinson J, Sharma P, Simonetto D, Jalal P, Orman E, Wadei H, St. Hillien S, Saly D, Ufere N, Dageforde L, Regner K, Belcher J, Patidar K, Consortium F. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics 2024, 60: 778-786. PMID: 39010302, PMCID: PMC11349455, DOI: 10.1111/apt.18159.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injuryAcute kidney injury phenotypesHepatorenal syndromeMELD-NaDevelopment of acute kidney injuryCumulative incidence of deathConsecutive adult patientsOutcomes of patientsAlcohol Abuse and Alcoholism (NIAAANon-AH groupRenal replacement therapyPresence of AHAcute tubular necrosisRetrospective cohort studyPredictors of mortalityIncidence of deathAKI stageClinical courseReplacement therapyAdult patientsKidney injuryCumulative incidencePoor prognosisTubular necrosisExploring Novel Adverse Events of Nefecon
Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney International Reports 2024, 9: 2705-2717. PMID: 39291217, PMCID: PMC11403076, DOI: 10.1016/j.ekir.2024.07.006.Peer-Reviewed Original ResearchAdverse eventsFood and Drug AdministrationFDA Adverse Event Reporting SystemSystem organ classNovel adverse eventsSubgroup analysisDisproportionate analysisFailure type profileUS Food and Drug AdministrationUS FDA Adverse Event Reporting SystemAdverse Event Reporting SystemMedical Dictionary of Regulatory ActivitiesEuropean Medicines AgencyClinical vigilanceEvent Reporting SystemSafety profileCumulative incidencePostmarketing dataIgA nephropathyClinical eventsPositive PTDrug AdministrationRelative riskMedicines AgencyClinical prioritySecond primary non-breast cancers in young breast cancer survivors
Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Winer E, Bellon J, Partridge A. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Research And Treatment 2024, 207: 587-597. PMID: 38858235, DOI: 10.1007/s10549-024-07400-z.Peer-Reviewed Original ResearchPrimary non-breast cancerNon-breast cancerSubdistribution hazard ratiosYoung breast cancer survivorsStage 0-III BCBreast cancer survivorsConfidence intervalsGray subdistribution hazard modelRisk factorsMedical record reviewPrimary BCBreast cancerCumulative incidenceBC survivorsCancer survivorsYoung breast cancerSubdistribution hazard modelPrimary tumor characteristicsMedian Follow-UpRecord reviewType of malignancyGermline geneticsHazard ratioLong-term surveillancePatient factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply